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Abstract
Objective: To correlate the postbronchodilator (post-BD) inspiratory capacity (IC), % of predicted, with other markers of severity and 
prognostic factors in chronic obstructive pulmonary disease (COPD). Methods: Eighty stable patients with COPD performed forced vital 
capacity and slow vital capacity maneuvers, as well as the 6-min walk test, prior to and after receiving albuterol spray (400 µg). Patients were 
divided into four groups, based on post-BD forced expiratory volume in one second. Several variables were tested to establish correlations 
with the post-BD distance walked, using univariate and multivariate analysis. Post-BD IC was found to correlated with Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) staging and with the Body mass index, airway Obstruction, Dyspnea, and Exercise capacity (BODE) 
index. Results: Multivariate regression analysis revealed that the distance walked, % predicted, correlated significantly with the IC post-BD, 
% predicted (p = 0.001), long-term oxygen use (p = 0.014), and number of medications used in the treatment (p = 0.044). IC ≤ 70% was 
observed in 56% patients in GOLD stages 3 or 4 vs. 20% in GOLD 1 or 2 (p < 0.001). IC ≤ 70% was observed in (60%) patients with BODE 
score 3 or 4 vs. (33%) BODE score 1 or 2 (p = 0.02). Conclusion: Post-BD IC% predicted is the best functional predictor of distance walked 
and is significantly associated with GOLD staging and BODE index. Therefore, we propose that the inspiratory capacity should be added to 
the routine evaluation of the COPD patients. 
Keywords: Pulmonary disease, chronic obstructive; Walking; Respiratory function tests; Inspiratory capacity.
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tion of dyspnea.(13) There is also a correlation between 
a lower IC/TLC ratio and higher mortality.(14) 
In addition to dynamic hyperinflation and skel-
etal muscle weakness, other factors, such as gas 
exchange abnormalities and pulmonary hyperten-
sion, contribute to exercise intolerance. Furthermore, 
patients with COPD frequently present smoking-
related diseases, such as hypertension and heart 
disease, which also contribute to limiting exer-
cise capacity. The 6MWT reflects all these factors, 
including the systemic effects associated with the 
disease and with airflow limitation.(15) 
Among the various respiratory function param-
eters, it would be interesting to select the one which 
correlates the most closely with exercise capacity, 
for inclusion in staging systems, since the contribu-
tion of the ventilatory part can vary, regardless of 
the degree of peripheral limitation.
The objective of the study was to evaluate how 
post-BD IC (% of predicted) correlates with other 
parameters of airflow limitation, such as forced 
vital capacity (FVC), post-BD FEV1 (% of predicted), 
FEV1/FVC, post-6MWT dyspnea, number of exacer-
bations, use of oxygen, and number of drugs used 
in the treatment, as well as with variables indi-
cating the prognosis and severity of COPD, such 
as the post-BD distance covered on the 6MWT 
(% of predicted), the BODE index, and the staging 
system proposed by the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD).
Patients and methods
This was a cross-sectional, descriptive study, 
comprising 80 stable patients with COPD. 
Inclusion criteria were as follows: being over 
35 years of age; having a smoking history of more 
than 20 pack-years; and presenting a post-BD FEV1/
FVC (% of predicted) lower than 70% in the func-
tional evaluation. Patients were selected from two 
Pulmonology Units in Brasília and were monitored 
for at least two months, presenting good compli-
ance with treatment, which was instituted according 
to symptoms and severity, as per the GOLD guide-
lines.(1) The following exclusion criteria were applied: 
presenting unstable disease; using high doses of 
oral corticosteroids (≥ 40 mg of prednisone); having 
used antibiotics within the four weeks preceding the 
study outset; and presenting uncontrolled comor-
bidities, such as myopathies, peripheral vascular 
Introduction
Chronic obstructive pulmonary disease (COPD) 
is a common, usually progressive and debilitating, 
disease that is characterized by airflow limitation. 
This disease is not fully reversible and is associated 
with a pulmonary inflammatory response to noxious 
particles or gases.(1) 
The staging of COPD is important in order to 
establish the prognosis and categorize the treat-
ment. An ideal staging system should strongly 
correlate with mortality, morbidity, and health 
status. Traditionally, the severity of COPD is 
defined by the degree of obstruction, evaluated by 
the forced expiratory volume in one second after 
bronchodilator use (post-BD FEV1). The cut-off 
points suggested for the measurement of FEV1 for 
staging vary, and there are significant differences 
among the guidelines issued by the various prestig-
ious pulmonology societies.(2-4) However, FEV1 does 
not correlate well with dyspnea, which is the most 
important symptom in patients with COPD.(5) The 
FEV1 value is not a good marker of survival, inci-
dence of hospitalization, and functional capacity, 
especially in more severe patients. In addition, the 
patient with COPD presents systemic manifestations 
which are not represented by FEV1.
Recent studies suggest that parameters other 
than FEV1 are important independent predictive 
prognostic factors in COPD, and that some are, in 
fact, better markers than FEV1.
(6-9) Such parameters 
include the following: body mass index (BMI); degree 
of dyspnea; distance covered on the 6-minute walk 
test (6MWT); health-related quality of life; oxygen 
uptake (VO2); the inspiratory capacity/total lung 
capacity (IC/TLC) ratio; the Body mass index, airway 
Obstruction, Dyspnea, and Exercise capacity (BODE) 
index; and the long-term use of oxygen.
Various factors account for exercise intolerance 
in patients with COPD, although airflow limitation 
and peripheral muscle dysfunction play important 
roles.(10,11) In COPD, the loss of lung elastic recoil and 
progressive expiratory airflow limitation promote 
air trapping, with increased functional residual 
capacity and decreased IC. Static hyperinflation and 
its increase during exercise (dynamic hyperinfla-
tion) have been associated with exercise intolerance 
in individuals with COPD.(11,12) Reduction of hyper-
inflation, expressed as an increase in post-BD IC, 
correlates with better exercise tolerance and reduc-
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and through multivariate analysis, with post-BD 
distance walked expressed as the percentage of 
predicted. Normality in the distribution of variable 
data was tested using the Kolmogorov-Smirnov 
test. A parametric test was used for those presenting 
normal distribution of data. When the distribution 
was not normal, a nonparametric test was applied. 
The level of statistical significance for the tests was 
set at p ≤ 0.05. Calculations were made using the 
Statistical Package for the Social Sciences, version 
12.0 (SPSS Inc., Chicago, IL, USA).
All participating patients gave written informed 
consent, and the study design was approved by 
the Ethics Committee of the University of Brasília 
School of Health Sciences.
Results
The general data of the 80 patients with COPD 
are shown in Table 1.
The study sample comprised 57 men and 
23 women. According to the GOLD classification, 
among those 80 patients, the obstruction was mild 
in 5 (6%), moderate in 29 (36%), severe in 34 (43%), 
and very severe in 12 (15%). Regarding the BODE 
index, 32 patients (40%) were classified in quartile 
1, 25 (31%) in quartile 2, 17 (21%) in quartile 3, and 
6 (8%) in quartile 4. A total of 15 patients (19%) 
presented BMI ≤ 21 kg/m2. The BMI correlated 
negatively with the GOLD score, in a significant, 
disease, and rheumatic/orthopedic diseases that 
impair locomotion, as well as coronary ischemia and 
arrhythmia.
The patients were divided into four groups by 
degree of obstruction, as proposed by the GOLD 
consensus,(1) according to post-BD FEV1: mild, 
moderate, severe, and very severe. In parallel, they 
were also divided into four groups according to 
the BODE index, which defines death risk.(2) They 
were submitted to traditional spirometry, including 
measurement of slow vital capacity and IC. After 
spirometry, the 6MWT was performed, according 
to the norms proposed by the American Thoracic 
Society, adding measurement of peripheral oxygen 
saturation (SpO2) before, during, and after the 
test.(16) All of the tests were repeated 15 minutes 
after inhalation of albuterol spray (400 µg). After 
the 6MWT, dyspnea was evaluated using the Borg 
scale. The rhythm of the walk was determined by 
the patients, who were accompanied and given oral 
encouragement standardized by the pulmonologist. 
The patients who used oxygen at home walked using 
oxygen.
The predicted values for the FVC maneuver 
and IC were based on the values suggested for the 
Brazilian population.(17,18) The values predicted for 
the distance walked were those already established 
in the literature.(19) 
Several variables were tested, through univar-
iate analysis, using Spearman’s and Pearson’s tests, 
Table 1 - General data in 80 patients with chronic obstructive pulmonary disease.
Variables Mean ± SD or % Minimum/maximum values
Age (years) 70 ± 8 52/86
Males (%) 71
BMI (kg/m2) 25 ± 4 15/40
Use of oxygen (%) 9
Number of exacerbations/year 2 1/5
Smoking (pack-years) 51 ± 24 20/145
Post-BD FVC (% of predicted) 80 ± 16 43/136
Post-BD FEV1 (% of predicted) 49 ± 18 15/101
FEV1/FVC% (found) 49 ± 11 28/69
Post-BD IC (% of predicted) 78 ± 22 37/157
Post-BD distance covered on the 6MWT (% of predicted) 88 ± 21 22-137
Post-BD distance covered on the 6MWT (m) 397 ± 99 88/606
Post-6MWT post-BD SpO2 (%) 88 ± 5 74/95
SD = standard deviation; BMI: body mass index; post-BD FEV1: forced expiratory volume in one second after bronchodilator use; 
post-BD FVC: forced vital capacity after bronchodilator use; post-BD FEV1/FVC%: Forced expiratory volume in one second/forced 
vital capacity after bronchodilator use, percentage found; Post-BD IC: Inspiratory capacity after bronchodilator use; 6MWT: 6-minute 
walk test; and Post-6MWT post-BD SpO2: peripheral oxygen saturation after the 6MWT and after bronchodilator use.
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ograde multivariate analysis, IC (% of predicted), 
post-6MWT Borg scale dyspnea score, and the 
number of drugs used in the treatment remained 
significant. Once again, % of predicted IC accounted 
for 38% of this variation, followed by dyspnea, the 
addition of which raised the r2 to 51%. The correla-
tion between IC and the distance covered on the 
6MWT (% of predicted) is shown in Figure 1.
The patients using oral corticosteroids covered 
a shorter distance on the 6MWT (% of predicted), 
compared to those who did not use corticosteroids 
(62 ± 24% vs. 92 ± 18%, t = 4.73, p = 0.000), as well 
as presenting lower % of predicted post-BD FEV1 
(32 ± 16% vs. 51 ± 17%, t = 3.44, p = 0.001). In 
the multivariate analysis, the use of oral corticoster-
oids remained significant in relation to the distance 
covered on the 6MWT when FEV1, the use of oxygen, 
and other relevant factors were included (p = 0.016).
Thirty-three patients presented a post-BD 
IC ≤ 70% of predicted. An IC ≤ 70% was observed 
in 26/46 patients (56%) in GOLD stages 3 or 4, 
compared to 7/34 patients (20%) in GOLD stages 
1 or 2 (χ2 = 10.41, p = 0.001; Figure 2). An IC ≤ 70% 
was observed in 14/23 patients (60%) with a BODE 
score of 3 or 4, compared to 19/57 patients with a 
BODE score of 1 or 2 (33%) (χ2 = 5.127, p = 0.02; 
Figure 3).
Discussion
The results presented suggest that post-BD IC 
(% of predicted) is a good marker of severity and 
albeit weak, manner (r = −0.26 p = 0.017), as well 
as with the BODE index, also weakly (r = −0.27, 
p = 0.015).
The distance covered on the 6MWT 
(% of predicted) did not differ by gender and did 
not correlate significantly with age, height, or 
BMI. In the patients with a BMI < 21 kg/m2, the 
distance covered on the 6MWT (% of predicted) 
was 81 ± 16%, compared to 89 ± 22% in the other 
patients (t = 1.32, p = 0.19).
Comorbidities such as systemic arterial hyper-
tension, coronary disease, arrhythmia, diabetes, and 
hypothyroidism were present in 42 patients. The 
distance covered on the 6MWT (% of predicted) in 
the group of patients with comorbidities was 84 ± 
20%, compared to 91 ± 22% in the group of patients 
without comorbidities (p = 0.11). The seven patients 
who used oxygen in the home, long-term, covered 
the shortest distance on the 6MWT, expressed in % 
of predicted, when compared to the patients who 
did not use oxygen (47 ± 20% vs. 92 ± 17%, t = 6.0, 
p = 0.0001). The distance covered on the 6MWT 
(% of predicted) correlated inversely with the annual 
number of exacerbations (rs = −0.29, p = 0.009), 
as did the distance covered on the 6MWT (% of 
predicted) with the number of drugs used in the 
treatment (rs = −0.46, p = 0.0001).
Among the functional variables obtained after 
the administration of bronchodilator, we found that 
the distance covered on the 6MWT (% of predicted) 
correlated with the following: % of predicted FVC 
(r = 0.42, p < 0.00); % of predicted FEV1 (r = 0.44, 
p < 0.001); % of predicted FEV1/FVC (r = 0.47, 
p < 0.001); number of drugs used in the treatment 
(r = −0.49, p < 0.001); GOLD ( r = −0.52, p < 0.001); 
BODE index (−0.60, p < 0.001); % of predicted 
IC (r = 0.61, p < 0.001); post-6MWT Borg scale 
score (r = −0.41, p < 0.001); and post-6MWT SpO2 
(r = 0.31, p = 0.005). Using multivariate regression 
analysis, three variables were significantly associ-
ated with the distance covered on the 6MWT (% of 
predicted): % of predicted post-BD IC (p < 0.001); 
long-term use of oxygen (p = 0.001); and number 
of drugs used in the treatment (p = 0.034). Using 
anterograde multivariate regression analysis, these 
three variables accounted for 59% of the varia-
tion in the distance covered on the 6MWT, IC alone 
accounting for 38%, and the use of oxygen and IC 
together accounting for 55%. Excluding the seven 
patients who used oxygen and repeating the anter-
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Figure 1 - Correlation between the distance covered on 
the 6-minute walk test and inspiratory capacity after 
bronchodilator use (post-BD IC), both expressed as the 
% of predicted.
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cantly with the GOLD stages of severity and the 
BODE index prognostic score.
The GOLD severity stages take into account the 
degree of obstruction based on post-BD FEV1 (% of 
predicted).(1) The GOLD stages 3 and 4, or < 50% 
FEV1 (% of predicted), correlated with <70% IC 
(% of predicted).
The BODE index contains a component that 
quantifies ventilatory disorder by FEV1, another that 
detects the perception of dyspnea, in addition to other 
independent components, which are the distance 
covered on the 6MWT and the BMI, which reflect 
the systemic consequences of COPD.(6) The score in 
points, based on these variables, is a better predictor 
of the prognosis of the disease, compared to FEV1 in 
isolation.(6) Decreased BMI is a good marker of COPD 
systemic involvement and has been associated with 
greater mortality.(6) However, we did not find a strong 
correlation between BMI and the distance covered 
on the 6MWT (% of predicted). The small number of 
patients presenting a BMI < 21 kg/m2 (n = 15) might 
have influenced this result.
The 6MWT has been increasingly used to comple-
ment the functional evaluation of patients with 
COPD, since it reflects the systemic manifestations 
of the disease and airflow limitation. The variation 
in the distance covered on the 6MWT correlates with 
changes in spirometry and with the survival of the 
patients with COPD. A recent longitudinal study,(20) 
for the first time, described the prognostic value of 
the distance covered on the 6MWT in patients with 
severe COPD. Regardless of accompanying comor-
bidities, the distance covered on the 6MWT was a 
better predictor of mortality than was FEV1 or BMI. 
In the advanced stage of the disease, the drop in 
the distance covered on the 6MWT is independent 
of the drop in FEV1.
(14,20) A limitation of the present 
study was not correlating IC (% of predicted) and 
the distance covered on the 6MWT (% of predicted) 
with mortality, which would have underscored the 
value of IC as a marker of COPD disease severity. 
There were 5 patients (8%) who died during the 
data collection period.
In the univariate analysis, we found the distance 
covered on the 6MWT (% of predicted) to present 
significant inverse correlations with the number of 
exacerbations per year, long-term use of oxygen, 
number of drugs, especially systemic corticoster-
oids, and Borg scale dyspnea score measured at the 
end of the test, as well as direct correlations with 
prognosis in COPD, since there was strong signifi-
cant correlation between IC (% of predicted) and 
the distance covered on the 6MWT (% of predicted), 
as well as since IC was found to correlate signifi-
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Figure 2 - Relationship between inspiratory capacity after 
bronchodilator use (post-BD IC), expressed as the % of 
predicted, and the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) staging of severity.
Figure 3 - Relationship between inspiratory capacity 
after bronchodilator use (post-BD IC), expressed as the % 
of predicted, and Body mass index, airway Obstruction, 
Dyspnea, and Exercise capacity (BODE) index, separated 
by quartiles.
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since these patients did the test using oxygen, 
which is known to increase the distance covered on 
the 6MWT.
Some authors(14) reported that hyperinflation, esti-
mated by the IC/TLC ratio, designated the inspiratory 
index, is a predictor of long-term survival in COPD, 
regardless of FEV1. This finding was confirmed in the 
long-term cohort study conducted by the National 
Emphysema Treatment Trial Research Group,(7) which 
determined the risk factors of greater mortality in 
patients with severe emphysema. The following 
factors were identified as markers of worse prognosis 
and predictors of greater mortality: old age; reduced 
BMI; use of oxygen; decreased exercise capacity, 
defined by maximum load achieved on a cycle ergom-
eter; emphysema predominant in the lower lobes; a 
lower IC/TLC ratio; and an altered BODE index. The 
determination of the IC/TLC ratio presupposes the 
measurement of TLC by plethysmography, available 
in few centers. The IC (% of predicted) is a noninva-
sive test and can be easily measured by the slow vital 
capacity maneuver. However, rigorous reproducibility 
criteria should be observed.(27) The unavailability of 
predicted values for IC is seen as a limitation in various 
countries, although this does not occur in Brazil.(18) 
Most studies estimate IC by analyzing pulmonary 
volumes rather than by simple spirometry.(7,14) 
In recent years, the role of hyperinflation in 
dyspnea and exercise intolerance in COPD has been 
clearly established.(28) The measurement of IC reflects 
the degree of hyperinflation in COPD, although it is 
also influenced by inspiratory muscle strength, as 
well as by the extent of the mechanical load imposed 
upon the muscles. The IC also provides information 
on the position of the tidal volume in the pressure-
volume curve of the respiratory system. A lower IC 
brings the TLC closer to the tidal volume, a region 
in which the pressure-volume ratio becomes alinear, 
increasing lung elastic recoil. In patients with COPD, 
an increased respiratory rate during exercise results 
in increased air trapping, as well as increasing 
the tidal volume, thereby creating greater elastic 
demand for inspiration. Hyperinflation upon exer-
tion in COPD was demonstrated with the walk test. 
Therefore, in the present study, IC was found to be 
the greatest determinant of the distance covered on 
the 6MWT, which is not surprising.
In one study of patients with COPD,(5) dyspnea 
was a better predictor of five-year survival than 
was the degree of airflow obstruction. Therefore, 
post-BD FVC (% of predicted), post-BD FEV1 (% 
of predicted), post-BD FEV1/FVC (% of predicted), 
post-BD IC (% of predicted), and post-6MWT, 
post-BD SpO2.
The distance covered on the 6MWT can be 
influenced by height, weight, age, gender, motiva-
tion, previous performance of the test, drugs used 
before the test, comorbidities, peripheral muscle 
strength, and use of supplemental oxygen.(16) Due 
to the influence of anthropometric variables on the 
distance covered on the 6MWT, we adopted the 
predicted values suggested in the literature for the 
North-American population.(19) Reference values for 
the 6MWT are not available for the Brazilian popu-
lation. Some studies evaluated the influence that a 
number of variables have on the distance covered on 
the 6MWT in COPD patients. However, depending 
on the study, some variables were measured, and 
others were ignored. A multivariate analysis of the 
factors that could influence the distance covered on 
the 6MWT, in a study involving 83 patients with 
COPD,(21) revealed that four factors accounted for 
78% of the total variance of the data: the heart 
rate pattern, exercise capacity, oxygen transport 
capacity, and dyspnea. The IC was not included in 
the data analysis. Muscle strength, including respi-
ratory muscle strength and upper-body strength, as 
well as the diffusing capacity of the lung for carbon 
monoxide, significantly influence the performance 
on the walk test in COPD patients.(22-24) However, 
these were not measured in the present study.
In the present study, we found a significant 
inverse correlation between the number of exac-
erbations and the distance covered on the 6MWT 
(% of predicted). In COPD, there is a significant 
reduction in skeletal muscle strength in patients 
hospitalized during exacerbation, compared to those 
hospitalized during the stable state. Over a three-
month period of hospitalization, the former present 
only partial recovery, which can be attributed to 
various factors.(25) The number of exacerbations is 
a risk factor of mortality, as is the long-term use 
of corticosteroids.(26) We found a significantly lower 
value of the distance covered on the 6MWT (% of 
predicted) in the group of patients using systemic 
corticosteroids. Similarly, we found a significantly 
lower value of the distance covered on the 6MWT 
(% of predicted) in the group of patients with long-
term use of oxygen, compared to those who did not 
use oxygen. This difference was underestimated, 
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dyspnea should be included as a variable for the 
evaluation of mortality in these patients. Various 
previous studies have demonstrated that dyspnea 
plays an important role in determining the distance 
covered on the 6MWT by patients with COPD.(24,29) 
Other authors(12) measured IC at rest and at 
the end of the 6MWT in patients with COPD and 
demonstrated, similar to what has been previously 
shown on cycle ergometer tests, that the drop in 
IC during exercise, which reflects hyperinflation, 
correlates with dyspnea, as measured using the Borg 
scale. The data were obtained before the use of 
bronchodilator, and the correlation between IC and 
the distance covered on the 6MWT was significant, 
albeit lower than that observed in the present study 
(r = 0.41 vs. r = 0.61). We always considered all 
functional variables after the use of bronchodilator, 
since severity scores suggest that the patient should 
be classified after the relief of bronchospasm. This 
can also result in better learning for the performance 
of the 6MWT, and in better correlation with IC.
A recent review article questioned the 
routine evaluation of dynamic hyperinflation by 
 measurement of IC during exercise through ergos-
pirometry.(30) The author emphasizes the value of 
cardiopulmonary exercise testing in COPD and, 
principally, the evaluation of post-exercise dyspnea 
reported by the patient, which would result from 
dynamic hyperinflation, more simply determined. In 
our study, dyspnea correlated significantly with the 
distance covered on the 6MWT (% of predicted), 
as well as with IC (% of predicted), which demon-
strates the multifactorial origin of dyspnea in COPD. 
However, hyperinflation during exercise, despite 
being the most important mechanism, does not 
completely explain the post-6MWT dyspnea.
In conclusion, post-BD IC (% of predicted) is a 
good predictor of the distance covered on the 6MWT, 
and is strongly associated with other markers of 
severity and prognosis in COPD, such as the GOLD 
staging and BODE index. We suggest that post-BD 
IC (% of predicted) be included in the routine func-
tional evaluation of patients with COPD. A 70% 
cut-off point can be used to classify the patients.
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